TP53 and cancer: It is reported that mutations in TP53 is not common in ovarian, endometrial, kidney, or pancreatic cancers, but these frequently accumulate mutations in chromatin-modifying genes, suggesting the existence of alternative pathways of carcinogenesis between these subsets of cancer [25]–[28].